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association with the  LPA SNP was replicated in the PRO-
spective Study of Pravastatin in the Elderly at Risk (PROS-
PER) trial ( P = 0.009). Using CARDS data, we further 
showed that atorvastatin therapy did not alter lipoprotein(a) 
[Lp(a)] and that Lp(a) levels accounted for all of the asso-
ciations of SNPs in the LPA gene and the apparent LDL-c 
response levels. However, statin therapy had a similar effect 
in reducing cardiovascular disease (CVD) in patients in the 
top quartile for serum Lp(a) levels (HR = 0.60) compared 
with those in the lower three quartiles (HR = 0.66;  P = 0.8 
for interaction). The data emphasize that high Lp(a) levels 
affect the measurement of LDL-c and the clinical estimation 
of LDL-c response.  Therefore, an apparently lower LDL-c 
response to statin therapy may indicate a need for measure-
ment of Lp(a). However, statin therapy seems benefi cial 
even in those with high Lp(a). —Deshmukh, H. A., H. M. 
Colhoun, T. Johnson, P. M. McKeigue, D. J. Betteridge, P. N. 
 Abstract  We carried out a genome -wide association study 
(GWAS) of LDL-c response to statin using data from partici-
pants in the Collaborative Atorvastatin Diabetes Study 
(CARDS; n = 1,156), the Anglo-Scandinavian Cardiac Out-
comes Trial (ASCOT; n = 895), and the observational phase 
of ASCOT (n = 651), all of whom were prescribed atorvasta-
tin 10 mg. Following genome-wide imputation, we combined 
data from the three studies in a meta-analysis. We found as-
sociations of LDL-c response to atorvastatin that reached 
genome-wide signifi cance at rs10455872 ( P = 6.13 × 10   9 ) 
within the  LPA gene and at two single nucleotide polymor-
phisms (SNP) within the  APOE region (rs445925;  P = 2.22 × 
10   16 and rs4420638;  P = 1.01 × 10   11 ) that are proxies for 
the   2 and   4 variants, respectively, in APOE. The novel 
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daily and followed for a median of 3.7 years. Allocation was dou-
ble blinded. Mean serum LDL-c concentration during baseline 
visits prior to randomization had to be   4.14 mmol/l (160 mg/
dl) and serum triglycerides   6.78 mmol/l (600 mg/dl). After 
randomization, total cholesterol (TC), HDL-C, and triglycerides 
were measured at one, two, and three months, and then every six 
months. Patients attended after an overnight fast. LDL-c was cal-
culated with the Friedewald formula ( 7 ), or if serum triglycerides 
exceeded 4.0 mmol/l, by removing VLDL by ultracentrifugation 
and then measuring the change in infranatant cholesterol con-
tent when LDL was removed by precipitation of apolipoprotein 
B-containing lipoproteins. For this genome-wide study, the analy-
ses were restricted to those randomized to atorvastatin, and the 
mean of two pretreatment LDL-c measurements was used as the 
baseline LDL-c and a weighted average of fi ve post-randomiza-
tion values within the fi rst year post-randomization was the out-
come measure or “on treatment LDL-c,” with weights (0.6 for 
month 1 and then 0.1 for measurements at 2, 3, 6, and 12 
months). Lipoprotein(a) concentrations were determined by an 
immunoturbidimetric assay with Immuno LEIA® reagents from 
Technoclone Ltd., Dorking, UK (now www.PathwayDiagnostics.
com), which is calibrated against the IFCC standard preparation 
PRM02. 
 ASCOT 
 Of 19,342 hypertensive patients (40–79 years of age with at 
least three other cardiovascular risk factors) who were random-
ized to one of two antihypertensive regimens in ASCOT, 10,305 
with nonfasting TC concentrations of 6.5 mmol/l or less (mea-
sured at the nonfasting screening visit) had been randomly as-
signed additional atorvastatin 10 mg or placebo. These patients 
formed the lipid-lowering arm of the study. For this genome-wide 
study, two subpopulations from ASCOT were included. The fi rst 
subpopulation included individuals randomized to 10 mg ator-
vastatin in whom pretreatment LDL-c was measured at the (fast-
ing) randomization visit and on-treatment LDL-c was calculated 
as the simple average of measures at the (fasting) visits 6 months 
and 12 months post-randomization. LDL-c was estimated using 
the Friedewald equation as in CARDS. Following the end of the 
randomization phase, there was an observational period. The 
second subpopulation included all individuals not originally ran-
domized to 10 mg atorvastatin (i.e., those randomized to placebo 
and those not eligible for the LLA) who were subsequently pre-
scribed atorvastatin 10 mg. For these individuals, pretreatment 
LDL-c was defi ned as the measurement on the last visit before or 
equal to date of starting atorvastatin, and on-treatment LDL-c was 
defi ned as the measurement taken from the fi rst visit after date of 
starting atorvastatin. 
 PROSPER (replication cohort) 
 All data were from the PROspective Study of Pravastatin in the 
Elderly at Risk (PROSPER) ( 8 ). PROSPER was a prospective mul-
ticenter randomized placebo-controlled trial to assess whether 
treatment with pravastatin diminishes the risk of major vascular 
events in elderly. Between December 1997 and May 1999, we 
screened and enrolled subjects in Scotland (Glasgow), Ireland 
(Cork), and the Netherlands (Leiden). Men and women 70–82 
years of age were recruited if they had preexisting vascular dis-
ease or increased risk of such disease because of smoking, hyper-
tension, or diabetes. A total number of 5,804 subjects were 
randomly assigned to pravastatin or placebo, of which 2,550 sub-
jects assigned to the Pravastatin arm of the trial were included in 
the present study. TC, HDL-C, and triglycerides were assessed af-
ter an overnight fast, at baseline, and at 3, 6, 12, 24, and 36 months 
post-randomization. LDL-C was calculated by the Friedewald 
formula. The pretreatment measurement was at baseline before 
Durrington, J. H. Fuller, S. Livingstone, V. Charlton-Menys, 
A. Neil, N. Poulter, P. Sever, D. C. Shields, A. V. Stanton, A. 
Chatterjee, C. Hyde, R. A. Calle, D. A. DeMicco, S. Trompet, 
I. Postmus, I. Ford, J. W. Jukema, M. Caulfi eld, and G. A. 
Hitman on behalf of the CARDS, ASCOT, and PROSPER 
investigators.  Genome-wide association study of genetic de-
terminants of LDL-c response to atorvastatin therapy: im-
portance of Lp(a).  J. Lipid Res. 2012.  53: 1000–1011. 
 Supplementary key words genetics • low density lipoprotein • LDL/
metabolism • lipoprotein(a)• statins 
 Statin therapy is now widely accepted for the primary 
and secondary prevention of cardiovascular disease (CVD) 
in certain patient groups. However, there is considerable 
variation in response to statin therapy that remains poorly 
understood. For example, in the Collaborative Atorvastatin 
Diabetes Study (CARDS) trial ( 1 ), among self-reported 
and pill count-validated compliant recipients of atorvasta-
tin 10 mg daily, the absolute change in LDL-c at one month 
post-randomization varied from   2 to   0.6 mmol/l, (5 th 
and 95 th centiles of the range), and the percentage lower-
ing from baseline varied from 67% to 22%. Understanding 
the pathways and determinants involved in this variation in 
response to therapy could lead to improved treatments. 
Even without understanding the pathways, identifying pre-
dictors of poorer response could identify those most in 
need of additional or alternative therapeutic strategies. 
 Two genome-wide association studies (GWAS) of statin 
response and several candidate gene association studies 
have been reported ( 2–5 ). From these, the only consistent 
fi nding is that variants in the  APOE gene region are associ-
ated with variation in LDL response. Here, we report a 
genome-wide analysis of LDL-c response from two ran-
domized clinical trials of atorvastatin, CARDS and the 
Anglo-Scandinavian Outcomes Trial (ASCOT) ( 6 ), to in-
vestigate genetic effects on LDL-c response to atorvastatin. 
We chose to model genetic determinants of LDL-c re-
sponse to atorvastatin among those assigned to atorvastatin 
in these trials. An alternative approach would be to model 
the interaction of genotype on the effect of atorvastatin on 
LDL-c using data from both placebo and active treatment 
groups. However, we did not consider this latter approach 
as optimal as testing for interactions is much less powerful 
than direct tests of association and as, in any case, we did 
not consider genetic effects on change LDL-c in the pla-
cebo groups to be plausible. 
 MATERIALS AND METHODS 
 Study populations and phenotype defi nition 
 Both trials were conducted with Ethics Committee/IRB ap-
proval, under good clinical practice guidelines and in accordance 
with the Declaration of Helsinki principles. Patients gave consent 
for genetic studies. 
 CARDS 
 Methods in CARDS have been described previously. In brief, 
2,838 patients with type 2 diabetes and no previous CVD were 
randomized to receive either placebo or atorvastatin 10 mg once 
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mated relatedness with PLINK, and those individuals with Pi_
HAT > 0.25(excluding fi rst- and second-degree relatives) were 
removed (n = 0). Only LDL-c values from time points at which 
the person was compliant with atorvastatin (based on pill count > 
80% ) were used. 
 ASCOT genotyping.  Genotyping was carried out on Hu-
manCNV370 (Illumina) array on 3,868 individuals at Centre 
National de Génotypage (CNG) in two batches. Samples were 
excluded if they had   5% missing data (two samples). SNPs 
were excluded based on the following criteria:  i ) they had been 
mapped to different chromosomes or positions in the different 
releases (two SNPs), or  ii ) they were polymorphic A/T or C/G in 
either release or in the combined dataset, or  iii ) they had call 
rate   97% in either release or in the combined dataset (47,744 
SNPs), or  iv )  they had HWE  P -value   10   7 in either release or in 
the combined dataset (8,502 SNPs). After applying the above ex-
clusions, samples were excluded if they had estimated related-
ness > 0.1875 (halfway cut point between second- and third-degree 
relatives), estimated using a using a subset of 101,954 SNPs ob-
tained by linkage disequalibrium (LD) -based pruning (87 dupli-
cates, 15 fi rst-degree relatives and 4 presumed second-degree 
relatives removed. Then SNPs were excluded if they showed sig-
nifi cant differences in allele frequency between the different 
batches at  P < 10   7 (20 SNPs), if they were monomorphic in the 
combined dataset (3,838 SNPs), if they were not in HapMap r22 
(12,817 SNPs) or had different alleles to HapMap r22 (6 SNPs), 
or if they showed signifi cant differences ( P < 10   7 using Fisher’s 
exact test) in allele frequency between the combined dataset and 
HapMap r22 (308 SNPs). After applying all the above exclusions, 
ancestry outliers were excluded (n = 143) by using ancestry prin-
cipal component analysis ( 11 ) on a subset of 100,905 SNPs se-
lected by LD-based pruning, and ancestry principal components 
(PCs) were calculated for the remaining 3,804 individuals. 
 PROSPER genotyping.  A whole genome-wide screening was 
performed in the sequential PHASE project. DNA was available 
for genotyping 5,763 subjects. Genotyping was performed with 
the Illumina 660K beadchip. After QC (call rate < 95%), 5,244 
subjects and 557,192 SNPs were left for analysis ( 12 ). 
 Statistical analysis 
 Imputation of genotypes.  The CARDS genotype data were 
combined with phased haplotypes from HapMap phase II CEU 
r22 to compute posterior probability distribution of genotype at 
all HapMap loci using the IMPUTE program ( 13 ). For ASCOT 
and PROSPER, genotypes at unmeasured SNPs were imputed us-
ing MACH ( 14 ) and phased haplotypes from HapMap CEU r22. 
For ASCOT, a randomly chosen subset of 400 individuals was 
used to estimate transition and emission probabilities (i.e., to es-
timate recombination rates between SNPs and per-SNP genotyp-
ing error rates) using MACH options “-greedy -r 100” for each 
(entire) chromosome in turn. Using these estimated rates (the .
rec and .erate fi les), genotypes were imputed for the whole sam-
ple of 3,804 individuals using MACH options “-greedy-mle-mlde-
tails” for each (entire) chromosome in turn. 
 CARDS data analysis.  The EIGENSTRAT program ( 15 ) was 
used to adjust for population structure. Using PLINK ( 16 ), we 
generated a pruned subset of 152,587 SNPs that are in approxi-
mate linkage equilibrium with each other in the CARDS dataset. 
Principal components analysis was undertaken using this subset 
of SNPs. Thirty-seven individuals identifi ed as outliers in the initial 
principal components analysis were excluded from the subse-
quent computation of principal components, leaving 1174 per-
sons evaluable for statin response. The fi rst three principal 
randomization, and the posttreatment was the mean of the lipid 
measurements after randomization. 
 Phenotype transformation 
 To maximize power to detect associations and to improve test 
statistic behavior under the null for low minor allele frequency 
(MAF ) single nucleotide polymorphisms (SNP), we transformed 
measured LDL-c levels to conform to the distributional assump-
tions made by our association analysis model using the same 
transformation for off- and on-treatment measures to preserve 
the relationship between the two. We maximized the fi t of the 
residuals in a regression of on-treatment on the pretreatment 
value to a Gaussian distribution. We used a 2-parameter Box-Cox 
transform of the form ? ?? αβ α/x  applied to baseline and on-
treatment LDL-c values. The parameter values   and   were 
chosen by maximizing the likelihood of a model with linear re-
gressions of the transformed pretreatment and response (trans-
formed pretreatment minus transformed pretreatment) values 
on the covariates (age and sex), with the joint distribution of 
the residuals from the two regression models being bivariate 
Gaussian. 
 The parameter values obtained were   = 0.156,   =   0.505 
mmol/l in CARDS. In ASCOT, the parameters were   = 0.6807, 
  = 0.8850 mmol/l in the randomized dataset, and   = 0.4805, 
  = 0.5813 mmol/l in the observational dataset. This transforma-
tion has the same motivation as the inverse normal transform 
used in some GWAS applications ( 9, 10 ), but the use of a para-
metric transform preserves the relationship between pre and on-
treatment measures, thereby allowing the difference between the 
two, adjusted for pretreatment value, to be used as a response 
variable as was done in ASCOT or as simply the on-treatment 
adjusted for pretreatment value as in CARDS (these are equiva-
lent). The effect sizes in discovery cohorts (CARDS and ASCOT) 
and the replication cohort (PROSPER) were scaled so that the 
residuals had unit variance, thereby allowing studies using differ-
ent transforms to be combined. 
 DNA extraction and genotyping 
 CARDS.  DNA was extracted from whole-blood EDTA sam-
ples. DNA was isolated from 10 ml of frozen blood using the Gen-
tra Puregene DNA Isolation Kit from Qiagen (Cat. no. 158389). 
Briefl y, RBC was lysed with an anionic detergent in the presence 
of a DNA stabilizer that limits the activity of intracellular DNases. 
White blood cells were collected by centrifugation at 2,000  g for 
2 min. RNA was removed by treatment with RNase A. Protein was 
removed by salt precipitation (centrifugation at 2000  g for 5 
min). Genomic DNA was recovered by precipitation with isopro-
panol and centrifugation at 2,000  g for 5 min, the DNA pellet was 
washed in 70% ethanol, air dried, and dissolved in hydration so-
lution (1 mM EDTA, 10 mM Tris·CI , pH 7.5). Purifi ed DNA was 
stored at   20°C. DNA aliquots were genotyped at Perlegen Sci-
ences using a proprietary SNP set comprising 599,164 SNPs. Of 
these, 243 SNPs that had discrepant map positions between Hap-
Map and Perlegen were dropped. We set a minimum SNP call 
rate threshold of 80% for including SNPs in the analysis, and we 
required that the  P -value for a test of deviation from Hardy-Wein-
berg equilibrium (HWE) was not < 10   5 . This gave 517,746 SNPs 
for analysis. The average call rate was 98%, with 86.25% SNPs 
with a call rate of greater than 90%. SNP annotation was based on 
build 36 of the Human Genome Sequence. All SNPs were used in 
the analysis regardless of allele frequency, but the allele fre-
quency was considered when evaluating putative associations. Al-
lele frequency was below 1% at 6% of SNPs. We selected samples 
from those people who had been allocated atorvastatin 10 mg 
daily, had given consent for genotyping, and had a sample SNP 
call rate > 80%. After applying the exclusions of HWE, we esti-
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studies) is obtained as a summary measure of the effi ciency of 
genotype imputation. For concise presentation, we focus here on 
showing the results of the meta-analysis rather than each study 
separately and provide study-specifi c estimates of effect only at 
the most extreme signifi cance levels. In the data presentation, 
those loci at which the overall proportion of information ex-
tracted was less than 30% across the studies have been excluded. 
We have used the  P -value threshold of <5 × 10   8 as the threshold 
for declaring a genome-wide signifi cant association. 
 Distinguishing indirect and direct effects of genotype on on-
treatment LDL.  Effects of genetic variation on treatment re-
sponse as measured by on-treatment LDL-c could be mediated 
through effects on the pretreatment LDL-c. To evaluate whether 
genetic on-treatment LDL-c likely refl ects residual effect on pre-
treatment LDL-c, it is necessary to adjust for the pretreatment 
LDL-c levels and to correct the maximum likelihood estimate of 
the adjusted effect of genotype on on-treatment value for the 
noise in pretreatment values (the noise is both random measure-
ment error and intra-individual variation in usual LDL-c). From 
the rules of path analysis, we calculated the direct effect   of geno-
type on an on-treatment trait value as        (1    	 ) /  	 , where   is 
the coeffi cient of regression for on-treatment trait value on geno-
type adjusted for measured pretreatment value,  	 is the intraclass 
correlation between replicate measurements of pretreatment val-
ues, and   is the coeffi cient of regression for on-treatment value 
on observed pretreatment value. For these calculations, we used 
 	 = 0.8 as a plausible value for the intraclass correlation based on 
the within-person correlation in LDL-c values taken over two pre-
treatment visits in CARDS. 
 RESULTS 
 Table 1  compares baseline characteristics of participants 
in the three studies.  Fig. 1  shows a quantile-quantile plot 
of the   log 10  P -values for association of each SNP with 
LDL-c response to treatment, obtained by meta-analyzing 
effect size estimates across the CARDS and ASCOT data-
sets. This plot shows that the cumulative distribution of 
test statistics approximates the null distribution over most 
of its range but that there is a tail of extreme results.  Fig. 2 
 shows a Manhattan plot of the   log 10  P -values by map posi-
tion.  Table 2  shows all loci at which the summary test for 
association yielded a nominal  P -value < 10   6 . The estimates 
of effect (  ) are for the transformed response variable 
(see Materials and Methods). In CARDS, the response 
variable was transformed on-treatment LDL-c with trans-
formed pretreatment LDL-c entered as a covariate in the 
model. This is mathematically equivalent to modeling 
change in LDL-c with pretreatment LDL-c as a covariate 
(i.e., the difference in transformed on-treatment and ad-
justment for pretreatment LDL) as was done in ASCOT. A 
negative   for an allele means that the modeled allele is 
associated with a bigger reduction in posttreatment LDL-c 
and a better response to statins. 
 The strongest associations were with rs10455872 in the 
 LPA gene on chromosome 6, and with SNPs in the 
 BCAM / PVRL2 / APOE / APOC1 gene region on chromosome 
19, where genome-wide signifi cant associations were 
found. The SNPs in the  LPA and  APOE region explained 
4% of the variance in LDL-c response in CARDS. The next 
components were retained and included as covariates in all tests 
of association. 
 On-treatment values for LDL-c for each individual at 1, 2, 3, 6, 
and 12 months post-randomization were available. We initially 
used the fi rst available post-randomization LDL-c and established 
that the previously reported APOE genotype at rs445925 was the 
strongest association in a genome-wide analysis of response at  P = 
1.1 × 10   13 . To maximize the power to detect any further new as-
sociations, we trained the weighting of post-randomization LDL-c 
time points to maximize the strength of the association of LDL 
response with  APOE genotype at rs445925. Based on this, the 
nonmissing values for each individual were combined in a 
weighted average, with the one-month value allocated a weight of 
0.6 and the four subsequent values, weights of 0.1 each ( P -value 
for rs445925 with these weights = 2.2 × 10   16 ). SNPTEST ( 13 ) was 
used to test for association of LDL response with genotype in a 
linear regression with the weighted average post-randomization 
LDL value as dependent variable and with covariates, including 
transformed pretreatment LDL-c, age, sex, and scores on the fi rst 
three principal components of population stratifi cation. The 
missing-data likelihood option was used to allow for uncertainty 
of genotypes at each imputed locus. In practice, the use of several 
weighted post-randomization LDL-c values rather than a single 
fi rst value made very little difference to the results (see supple-
mentary table II). 
 We used the conditional analysis test in PLINK ( 16 ) to test for 
independence of SNP associations over short regions within the 
same gene; a null model based on equating the effects of haplo-
types that differed only at the SNP under test was compared with 
a more general model in which the effects of these haplotypes 
were unconstrained. The null hypothesis is that the SNP under 
test accounts for all associations of haplotypes with response. 
Other analyses included those carried out to explore initial asso-
ciations, including a test of whether LPA genotype modifi es the 
effect of atorvastatin on CVD. This was carried out by estimating 
the hazard ratio associated with allocation to atorvastatin in a 
Cox regression model of time to fi rst CVD event and using a like-
lihood ratio test comparing a model with this main treatment ef-
fect and one including a term for interaction of genotype × 
treatment effect. 
 ASCOT data analysis.  We regressed the response variable 
(transformed on-treatment minus transformed pretreatment 
LDL-c) onto imputed expected genotype dosage as implemented 
in ProbABEL ( 14, 17 ). This is asymptotically equivalent to score 
test for taking into account uncertainty in imputed genotypes (as 
in SNPTEST) but with improved fi nite sample size operating 
characteristics ( 18 ). Age, sex, age*sex, and transformed pretreat-
ment LDL were used as covariates, plus 10 ancestry principal 
components. 
 PROSPER data analysis.  The response variable was re-
gressed (natural log of transformed on-treatment minus natural 
log of pretreatment LDL-c) onto imputed expected genotype 
dosage as implemented in SNPTEST. Age, sex, transformed pre-
treatment LDL, and top three principal components were used 
as covariates. 
 Meta-analysis.  The score and observed information for the 
effect parameter were summed over studies to obtain a summary 
score test. This is algebraically equivalent (based on the quadratic 
approximation of the log-likelihood) to obtaining a weighted av-
erage of the maximum likelihood estimates with weights inversely 
proportional to the squared standard errors, with the useful fea-
ture that the ratio of observed to complete information (calcu-
lated by summing numerators and denominators over the three 
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change in LDL-c with statin therapy at one month was ap-
proximately   43% in those with at least one “G” allele at 
rs10455872 (MAF = 8%) compared with   46.5% in ho-
mozygotes for the “A” allele. There was no signifi cant ef-
fect of this SNP on change in LDL-c post-randomization in 
those in the placebo group ( P = 0.28). 
 To investigate the association with  LPA genotype fur-
ther, we fi rst confi rmed that  LPA genotypes predicted 
serum lipoprotein(a) [Lp(a)] levels, which had been mea-
sured in CARDS but not in ASCOT.  Fig. 4  shows the re-
sults of the GWAS for serum Lp(a) levels; all signifi cantly 
associated loci were in the  LPA region, consistent with 
other reports ( 19 ). In a linear regression model that included 
age, sex, and population structure covariates, 12 SNPs in 
the  LPA region had independent effects on serum Lp(a) 
(rs10455872, rs5014650, rs783147, rs6919346, rs3103349, 
most signifi cant  P -value was that for the  ALG10 region on 
chromosome 12, but this did not reach genome-wide sig-
nifi cance. There was no evidence of gene-gender interac-
tion for all the top SNPs reported in the study. The effect 
sizes for all top SNPs were similar in CARDS, where all the 
participants had type 2 diabetes, and in ASCOT, where 
21% of the participants had type 2 diabetes ( Table 2 ), sug-
gesting that diabetes per se was not a strong determinant 
of the genetic effect of the top SNPs. 
 LPA 
 In the  LPA gene SNP, rs10455872 showed a genome-
wide signifi cant association with LDL-c response ( Fig. 3 ). 
 The effect at rs10455872 was modest; the   shown in  Table 
2 is not easily directly interpretable given the transforma-
tion used, but in CARDS, for example, the percentage 
 Fig.  1. Quantile-quantile plot of meta-analysis  P- values for statin response. A plot of the quantiles of ob-
served and expected distribution of  P- values against each other. 
 TABLE 1. Characteristics of patients and studies included in the meta-analysis 
CARDS ASCOT-R ASCOT-Obs
 n = 1194  n = 895  n = 691 
Age (mean years ± SD) 61.6 ± 8.2 64.1 ± 8.0 64.2 ± 8.6
Ethnicity Caucasian 
(UK and Ireland)
Caucasian 
(UK and Ireland)
Caucasian 
 (UK and Ireland)
Women (%) 47 11.0 13.1
Diabetes (%) 100 21 21
Follow-up years 
(median IQR)
3.9 years (3.0–4.7) First year was used First year was used
Hypertension (%) 87 100 100
LDL-c level at baseline 
(mean mmol/l ± SD)
3.04 ± 0.71 3.47 ± 0.70 3.75 ± 0.85 a 
Lipid entry criterion Fasting LDL-c   4.14 
mmol/l
Non-fasting TC   6.5 
mmol/l
None
Fasting status for lipids b Overnight fast Fasting Fasting
Statin dose Atorvastatin 10 mg daily Atorvastatin 10 mg daily Atorvastatin 10 mg daily
Platform Perlegen 6 Illumina HumanCNV370 Illumina HumanCNV370
pHWE c exclusion 10   5 10   7 10   7 
Imputation software IMPUTE 2 MACH MACH
NCBI build for imputation HapMap CEU r22 HapMap CEU r22 HapMap CEU r22
ASCOT-Obs, observational arm of ASCOT; ASCOT-R, randomized arm of ASCOT.
 a In N = 656 with nonmissing LDL-c at baseline; the missingness is nonrandom because these are individuals 
with baseline triglycerides too high for Friedewald formula.
 b Fasting status for LDL-c at baseline (see previous row) and for response to statin measure.
 c P -value threshold for exclusion of SNPs not in HWE.
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(30%) with median levels being 7.6 mg/dl [interquartile 
range (IQR) 4.1–14 mg/dl], 50.5 mg/dl (IQR 37–68 mg/dl) 
and 55.2 mg/dl (IQR 51–113 mg/dl) in those with AA, 
AG, and GG genotype, respectively. We then adjusted the 
rs2063347, rs6415084, rs10455782, rs394487, rs6926458, 
rs316174, rs3127569). Together, these SNPs explained 
40% variation in the serum Lp(a) levels in CARDS; how-
ever, most of this was attributable to the rs10455872 SNP 
 TABLE 2. Combined analysis (CARDS, ASCOT randomized, and ASCOT observational) 
CHR POS (cM) SNP
Modeled 
Allele
Minor Allele 
(Frequency)
CARDS Ascot-R Ascot-Obs Meta-analysis
 P Gene c   SE   SE   SE Rsq a   b SE
6 195.419 rs10455872 A G (0.07)   0.35 0.08   0.36 0.11   0.1 0.18 0.54   0.35 0.06 6.13E-09 LPA
12 55.598 rs1627770 G T (0.2) 0.18 0.05 0.13 0.05 0.17 0.06 1 0.17 0.03 1.81E-07 LOC390301-ALG10
12 55.598 rs863626 C T (0.2) 0.18 0.05 0.13 0.05 0.17 0.06 1 0.18 0.03 1.39E-07 LOC390301-ALG10
12 55.598 rs11053045 A T (0.2) 0.18 0.05 0.13 0.05 0.17 0.06 1 0.18 0.03 1.34E-07 LOC390301-ALG10
12 55.598 rs1619785 A A (0.2)   0.18 0.05   0.13 0.05   0.17 0.06 1   0.18 0.03 1.28E-07 LOC390301-ALG10
12 55.599 rs10844779 A A (0.2)   0.18 0.05   0.14 0.05   0.17 0.06 1   0.18 0.03 1.44E-07 ALG10-LOC260338
12 55.599 rs11053068 C C (0.2)   0.18 0.05   0.14 0.05   0.17 0.06 1   0.18 0.03 1.44E-07 ALG10-LOC260338
12 55.599 rs5004272 A G (0.21) 0.18 0.05 0.12 0.05 0.17 0.06 1 0.17 0.03 2.81E-07 ALG10-LOC260338
12 55.599 rs10844823 C C (0.21)   0.18 0.05   0.12 0.05   0.17 0.06 0.99   0.17 0.03 2.86E-07 ALG10-LOC260338
16 27.656 rs721843 C G (0.46) 0.13 0.04 0.12 0.05 0.14 0.05 0.97 0.14 0.03 6.05E-07 LOC653737-GRIN2A
19 80.713 rs4803760 C T (0.2) 0.24 0.06 0.08 0.05 0.19 0.07 0.97 0.18 0.04 4.23E-07 BCAM-PVRL2
19 80.766 rs1985096 A A (0.16)   0.33 0.07   0.16 0.06   0.28 0.08 0.8   0.27 0.04 9.49E-11 BCAM-PVRL2
19 80.877 rs395908 A A (0.16)   0.21 0.06   0.1 0.06   0.23 0.07 0.92   0.19 0.04 3.46E-07 PVRL2-BCAM-TOMM40
19 80.954 rs6857 C T (0.14)   0.32 0.07   0.06 0.07   0.23 0.08 0.93   0.23 0.04 7.43E-08 PVRL2-BCAM-TOMM40
19 81.023 rs405509 G T (0.48)   0.17 0.05   0.1 0.04   0.21 0.05 0.99   0.17 0.03 3.46E-09 APOE-TOMM40-APOE
19 81.051 rs445925 A A (0.11)   0.44 0.08   0.36 0.07   0.34 0.09 0.77   0.42 0.05 1.59E-17 LOC100129500-APOE 
 APOC1
19 81.081 rs4420638 A G (0.16)   0.44 0.08   0.15 0.07   0.32 0.09 0.56   0.33 0.05 1.12E-11 APOC1 APOC1 APOC4
SNPs associated with LDL-c response to statins with meta-analysis values of  P < 10   6 and Rsq > 0.30.
Ascot-Obs, ASCOT observational; Ascot-R, ASCOT randomized; CHR, chromosome; POS, position.
 a Estimate of squared correlation between imputed and true genotypes.
 b A positive   value means that the modeled allele is associated with a bigger posttreatment LDL-c and, therefore, a lower response to statins. A 
negative   value means that the modeled allele is associated with lower posttreatment LDL-c and, therefore, a better response to statins.
 c For SNPs that lie in the intergenic regions, the location of the nearby genes is shown.
 Fig.  2. Manhattan plot of  P -values from meta-analysis of all SNPs that passed stringent quality control. The Manhattan plots [also known 
as   log 10 ( P ) association plots[ show the chromosomal position of SNPs exceeding the genome-wide signifi cance threshold ( P < 5 × 10 
  8 ) 
as indicated by the solid red line. 
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effect of statin on Lp(a) levels;   was   0.23 mg/dl, (95% 
CI:   2.25 to 1.80) for difference in Lp(a) levels with ator-
vastatin versus placebo at one year post-randomization, 
adjusted for baseline Lp(a), age, and sex. 
 To assess whether serum Lp(a) levels might alter effi -
cacy of statin therapy on CVD itself, we examined whether 
there was any evidence of interaction (deviation from a 
multiplicative model of joint effects on a hazard scale) be-
tween high serum Lp(a) levels and atorvastatin on CVD 
end points in CARDS. The hazard ratio for CVD events 
associated with statin use was 0.60 (95% CI: 0.32–1.13) 
among those in the top quartile for serum Lp(a) (>22 mg/dl) 
compared with 0.66 (95% CI: 0.46–0.93) among those 
association of genotype at SNPs in the  LPA gene with 
LDL-c response to statin for measured serum Lp(a) levels 
in the CARDS data to test whether the genetic effects seen 
are likely to be mediated through the effect of  LPA on 
serum Lp(a) levels ( Table 3 ).  The estimate of the stan-
dardized regression coeffi cient at the associated SNP 
(rs10455872) in  LPA in CARDS was reduced from   0.35 
(±0.08) to   0.09 (±0.08), consistent with the effect of gen-
otype on apparent response to statin being mediated 
through Lp(a) levels. We noted that Lp(a) levels had an 
independent association with apparent LDL-c response to 
statin beyond genotype in these analyses ( P = 0.001). Fur-
ther analysis in CARDS also confi rmed that there was no 
 Fig.  3. Regional association plot of LPA locus with statin response. Correlations between the target SNP 
(the SNP with the lowest  P value, depicted in purple) and nearby SNPs within a 500 kb region. The  r 2 values 
were based on the HapMap CEU population. 
 Fig.  4. Regional association plot of LPA locus with Lp(a) levels in the CARDS dataset. Correlations be-
tween the target SNP (the SNP with the lowest  P value, depicted in purple) and nearby SNPs within a 500 kb 
region. The  r 2 values were based on the HapMap CEU population. 
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16 events among the 294 trial participants with at least one 
copy of the G allele. 
 Replication of the LPA SNP 
 We tested the effect of  LPA SNP (rs10455872) in 2,550 
participants in the PROSPER trial randomized to 40 mg/
day of pravastatin. In this study, “A” allele of rs10455872 
was also associated with lower response to statins with a 
scaled   of –0.18 ± 0.04,  P = 0.009. The combined  P -value 
for the three studies was 1.2E-09 (  =   0.28 ± 0.04). 
with serum Lp(a) below this level (likelihood ratio test for 
interaction  P = 0.8). 
 Nor was there any evidence of interaction between 
rs10455872 genotype at  LPA and atorvastatin for effects on 
CVD end points ( P = 0.27 for the interaction of genotype 
at rs10455872 locus). Here the HR associated with atorvas-
tatin in those homozygous for the A allele was 0.58 (95% 
CI: 0.41–0.83) and the HR in those with at least one G al-
lele was 1.03 (95% CI: 0.38–2.78). However, the power to 
detect such an interaction was limited as there were only 
 TABLE 3. Effect of adjustment for serum Lp(a) levels in CARDS 
CHR POS (cM) SNP
Modeled 
Allele
Minor Allele 
(Frequency)
Before Lp(a) Adjustment After Lp(a) Adjustment
  SE  P   SE  P Gene a 
6 195.419 rs10455872 A G (0.07)   0.35 0.08 1.12E-05   0.09 0.08 2.96E-01 LPA
12 55.598 rs1627770 G T (0.2) 0.18 0.05 5.08E-04 0.19 0.05 3.21E-04 LOC390301-ALG10
12 55.598 rs863626 C T (0.2) 0.18 0.05 3.83E-04 0.19 0.05 2.48E-04 LOC390301-ALG10
12 55.598 rs11053045 A T (0.2) 0.18 0.05 3.73E-04 0.2 0.05 2.40E-04 LOC390301-ALG10
12 55.598 rs1619785 A A (0.2)   0.18 0.05 3.60E-04   0.2 0.05 2.28E-04 LOC390301-ALG10
12 55.599 rs10844779 A A (0.2)   0.18 0.05 4.22E-04   0.19 0.05 2.79E-04 ALG10-LOC260338
12 55.599 rs11053068 C C (0.2)   0.18 0.05 4.27E-04   0.19 0.05 2.82E-04 ALG10-LOC260338
12 55.599 rs5004272 A G (0.21) 0.18 0.05 5.82E-04 0.19 0.05 4.14E-04 ALG10-LOC260338
12 55.599 rs10844823 C C (0.21)   0.18 0.05 5.88E-04   0.19 0.05 4.19E-04 ALG10-LOC260338
16 27.656 rs721843 C G (0.46) 0.13 0.05 4.67E-01 0.13 0.04 3.69E-01 LOC653737-GRIN2A
19 80.713 rs4803760 C T (0.2) 0.24 0.06 3.43E-05 0.23 0.06 7.73E-05 BCAM-PVRL2
19 80.766 rs1985096 A A (0.16)   0.33 0.07 8.31E-07   0.33 0.07 1.39E-06 BCAM-PVRL2
19 80.877 rs395908 A A (0.16)   0.21 0.06 2.10E-04   0.21 0.06 3.65E-04 PVRL2-BCAM-
 TOMM40
19 80.954 rs6857 C T (0.14)   0.32 0.07 1.85E-06   0.3 0.07 1.75E-05 PVRL2-BCAM-
 TOMM40
19 81.023 rs405509 G T (0.48)   0.17 0.05 3.36E-04   0.14 0.05 4.31E-03 APOE-TOMM40-
 APOE
19 81.051 rs445925 A A (0.11)   0.44 0.08 1.13E-08   0.42 0.08 1.39E-07 LOC100129500-
 APOE APOC1
19 81.081 rs4420638 A G (0.16)   0.44 0.08 1.65E-08   0.43 0.08 1.39E-07 APOC1 APOC1 
 APOC4
Effect of adjustment for serum Lp(a) levels in CARDS for SNPs associated with an LDL-c response to statins with a meta-analysis of  P <10   6 .
CHR, chromosome; POS, position.
 a For SNPS that lie in the intergenic regions, the location of the nearby genes is shown.
 Fig.  5. Regional association plot of APOE locus with statin response. Correlations between the target SNP 
(the SNP with the lowest  P value, depicted in purple) and nearby SNPs within a 500 kb region. The  r 2 values 
were based on the HapMap CEU population. 
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Thus we tested for residual effects of SNP haplotypes con-
ditioning either on rs445925 (as a proxy for rs7412) or on 
rs4420638 (as a proxy for rs429358). When conditioned 
on rs4420638, the  
 4 proxy, the additional percentage 
variance explained by residual haplotype effects is 0.7% (F 
statistic with 8 and 854, df = 3.21,  P = 0.001). When condi-
tioned on rs445925, the proxy for  
 2, the additional per-
centage variance explained by residual haplotype effects is 
only 0.2% (F statistic with 8 and 854, df = 1.76,  P = 0.08), 
suggesting that  
 2 accounts for most of the variance in re-
sponse at this locus. 
 ALG10 
 Beyond these associations of LDL-c response with  APOE 
and  LPA, no other genome-wide signifi cant associations 
were found. The next most signifi cant SNPS were those in 
the ALG10 gene region ( Fig. 6 )  on chromosome 12 where 
several SNPs had  P < 10   6 . ALG10 codes for asparagine-
linked glycosylation protein 10 homolog A. Of these SNPs, 
most map to intergenic regions either side of the ALG10 
gene itself with one imputed SNP within ALG10 having a 
 P -value for association with statin response of 6.79 × 10   6 . 
 Effect of pretreatment LDL-C 
 To demonstrate that these fi ndings are unlikely to be 
confounded by baseline LDL-c,  Table 4  shows unadjusted, 
adjusted, and corrected estimates of the direct effect of 
genotype on posttreatment LDL at the strongest SNPs for 
the  APOE region  LPA and  ALG10 in the CARDS dataset. At 
the  APOE  
 2 proxy SNP (rs445925), without adjusting for 
baseline LDL-c, the apparent LDL-c response to statins 
would be more than double that observed in our baseline-
adjusted model (  =   1.01 vs.   0.44 per copy of “A” al-
lele), emphasizing the effect of adjusting for baseline 
LDL-c. However, adjusting our effect size estimate further 
by modeling measurement noise at baseline reduced the 
apparent effect just slightly to   =   0.30, suggesting there 
 APOE 
 Several SNPs in the  BCAM/PVRL2 / APOE / APOC1 / APOE 
gene region reached genome-wide signifi cance for statin 
response ( Fig. 5 ).  The effect on LDL-c response to statin 
therapy associated with these SNPs at in this region was 
modest; in CARDS for example the % change in LDL-c 
with statin therapy at one month was approximately -51% 
in those with at least one “A” allele at rs445925 compared 
with -45% in common GG homozygotes and was approxi-
mately -37% in those with at least one “G” allele at 
rs4420638 compared with -47% in common “AA” homozy-
gotes. These effects were independent of the effect of gen-
otype at rs10455872 in  LPA and of Lp(a) levels. In the 
CARDS dataset we confi rmed that there was no signifi cant 
effect of these SNPs on change in LDL-c post randomiza-
tion in those in the placebo group ( P = 0.47). 
 We examined whether the effects in this region could 
be accounted for by the known  
 2/ 
 3/ 
 4 protein poly-
morphism of apolipoprotein E, which corresponds to 
 APOE SNP haplotypes T-T, T-C, and C-C, respectively, at 
rs429358 and rs7412. The presence of the “T” allele at 
rs7412 contrasts the  
 2 protein variant with other protein 
variants, whereas presence of the “C” allele at rs429358 
contrasts the  
 4 protein variant with other protein vari-
ants. These two SNPS were not directly typed and could 
not be imputed as they are not in the HapMap II. 
 The “A” allele at rs445925, which we found to be associ-
ated with a higher statin response (  =   0.44) is in LD 
with the “T” allele at rs7412 with a reported  r 2 of 0.76; thus, 
it is a proxy for the  
 2 protein variant ( 20 ). The “G” allele 
at rs4420638, which was associated with lower response to 
statin, is in LD with the “C” allele at rs429358 with reported 
 r 2 of 0.62 but with a low  r 2 of 0.01 for rs7412 ( 21 ); thus, it is 
a proxy for the  
 4 protein variant. 
 These two proxy SNPs are in the HapMap and could be 
imputed in this analysis with percentage information con-
tent (i.e., imputation quality) of 77% and 56%, respectively. 
 Fig.  6. Regional association plot of ALG10 locus with statin response before Lp(a) adjustments. Correla-
tions between the target SNP (the SNP with the lowest  P value, depicted in purple) and nearby SNPs within 
a 500 kb region. The  r 2 values were based on the HapMap CEU population. 
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highly skewed distribution; for example, in CARDS, the 
median serum Lp(a) was 8.9 mg/dl (IQR 4.5–21.3 mg/dl) 
and with values as high as 238 mg/dl. Approximately 30% 
of variance in Lp(a) levels has been reported as deter-
mined by the kringle IV type 2 (KIV-2) copy number vari-
ant in  LPA , which is known to encode variability in the size 
of apo(a). Some variance in measured Lp(a) attributable 
to genes is also due to apo(a) size heterogeneity affecting 
the results of the immunochemical methods used to quan-
tify Lp(a), as is the case with the assay we used ( 22 ). That 
is, genotype can induce some measurement error in Lp(a), 
although recent data from the Framingham study suggest 
the measurement error is likely to be of little practical im-
portance ( 23 ). The Lp(a)-raising genotype associated with 
the kringle repeat and high Lp(a) levels themselves have 
also been reported to be associated with increased car-
diovascular risk in several studies ( 24–28 ). As such, re-
cent guidelines emphasize the importance of detecting 
high Lp(a) phenotype and possible intervention with nia-
cin ( 26 ). 
 The rs10455872 SNP that we found associated with 
LDL-c response is in strong LD with the KIV-2 copy num-
ber variant in Lp(a) ( 29 ). Consistent with this, variation at 
rs10455872 accounted for 30% of variance in Lp(a) in the 
CARDS data. However, the explanation for the apparently 
lower LDL-c response in those with genotypes associated 
with high Lp(a) lies in understanding what LDL-c estima-
tion actually captures. The standard Friedewald formula 
calculates LDL-c levels from TC, HDL-cholesterol, and 
plasma triglyceride and actually includes the cholesterol 
that resides in Lp(a). For most patients, this is of little im-
portance as usually only about 5% of what is measured as 
LDL-cholesterol is estimated to reside in Lp(a). However, 
it is estimated that about 8% of apparent LDL-c resides in 
Lp(a) if Lp(a) levels are in the range 30–60 mg/dl and as 
much as 20% if Lp(a) is > 60 mg/dl ( 30 ). As we show de-
fi nitively here in the CARDS trial, statin therapy did not 
lower Lp(a) levels. Thus, individuals who had an appre-
ciable fraction of their total plasma cholesterol carried on 
Lp(a) particles had some cholesterol in statin-responsive 
LDL particles and some in statin-unresponsive Lp(a) par-
ticles. For such patients, true LDL-c response will be un-
derestimated because apparent on-treatment LDL-c will 
comprise truly falling LDL-c but static Lp(a) levels. This 
phenomenon has previously been noted in the context of 
nephrotic syndrome ( 31 ) and has been emphasized by 
Scanu et al. ( 32 ). Our estimate that those with at least one 
copy of the Lp(a)-raising G allele at rs10455872 have about 
a 5 percentage points lower apparent statin response (45% 
in “GG” and “AG” genotype vs. 40% in “AA” genotype) 
and that this association disappears when adjusted for 
Lp(a) levels is consistent with these observations . 
 Although the effect of the G allele on statin response is 
modest, this allele only accounts for about 30% of variance 
in Lp(a) levels. The data highlight a more general clinical 
point that individuals with raised Lp(a) levels for any rea-
son have a somewhat lower apparent response to statin 
therapy and, therefore, that an apparently lower LDL-c 
response to statin may be an indication for checking Lp(a) 
is little residual effect of baseline due to measurement 
noise. At the  APOE  
 4 proxy SNP and at the  LPA SNP, the 
estimated effect of baseline LDL-c adjustment is much 
less, and thus, the adjustment for measurement noise al-
ters the association only slightly. 
 Other genes of interest 
 Previously reported variants associated with statin re-
sponse in the  PCSK9 (rs11591147),  HMGCR (rs1047443, 
rs17671591, rs6453131),  KIF-6 (rs20455),  ABCB1 (1236/
2677/3435 TTT haplotype),  CLMN (rs80141914, associ-
ated with TC response to statin), and  GCKR (rs1260326 
associated with triglyceride level response to statin) genes 
were not signifi cantly associated at with LDL-c response to 
statin in this study at an accepted genome-wide association 
threshold ( P   10   8 ) or even at thresholds typically ex-
pected to declare replication (say,  P   10   2 ) . However, 
 PCSK9 (rs11591147) and  GCKR (rs1260326) were signifi -
cant at a threshold of 0.05 (see supplementary Table I). 
We have refrained from comparing the directionality and 
magnitude of these effects in the present study because of 
the different phenotype characterization and transforma-
tions across the studies and, in some studies, lack of infor-
mation about the modeled alleles. 
 DISCUSSION 
 In this genome-wide association study of LDL-c response 
to atorvastatin therapy, we report that those with geno-
types in the  LPA gene that lead to higher Lp(a) levels have 
an apparently lower LDL-c response to statin, and we rep-
licate the previously reported association of a higher re-
sponse to statin in those with the A allele at the  APOE  
 2 
locus. The top three SNPs in the study, rs10455872 in  LPA 
and the  APOE  
 2 and  APOE  
 4 variants, explained only 4% 
variance in the LDL-c response to statin treatment; however, 
it is possible that that larger studies might detect more SNPs 
with smaller effect sizes or that there are larger effects at rarer 
variants not captured by our imputed genotypes. 
 LPA 
 Lipoprotein(a) is a plasma lipoprotein consisting of a cho-
lesterol-rich LDL particle with one molecule of apolipopro-
tein B100 and an additional protein, apolipoprotein(a), 
attached via a disulfi de bond. Serum levels of Lp(a) have a 
 TABLE 4. Effect of genotype on posttreatment LDL-c (CARDS only) 
SNP 
  unadjusted for 
baseline LDL
  adjusted for 
observed baseline 
LDL but uncorrected 
for measurement 
noise
  adjusted for 
baseline LDL and 
corrected for 
measurement 
noise
rs445925   1.01   0.44   0.38
rs4420638   0.54   0.44   0.42
rs10455872 
( LPA )
  0.49   0.35   0.32
rs10844779 
( ALG10 )
  0.18   0.18   0.18
With and without correction for measurement noise in baseline 
LDL.
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superset of 5,745 individuals studied for candidate gene 
associations only, three SNPs in  APOE and one SNP in 
 PCSK9 reached genome-wide signifi cance ( 2 ). In a meta-
analysis of three trials that included 3,932 treated subjects 
( 3 ) a SNP in the  CLMN gene was signifi cant at  P < 10   7 for 
association with TC response, and there was a weak asso-
ciation with SNP in  APOE. In the same study, polymor-
phism in the  GCKR gene was shown to be associated with 
statin-induced change in triglycerides. Candidate gene 
analyses have shown that a common  LDLR 3-UTR haplo-
type is associated with attenuated lipid-lowering response 
to simvastatin treatment ( 34 ). In the same study,  HMGCR 
gene polymorphisms were also associated with reduced 
plasma LDL-c and with reduced LDL-c response to simvas-
tatin. The association of  HMGCR gene with statin response 
was also reported in a population-based cohort of patients 
with diabetes ( 35 ). These effects were more evident in Af-
rican-Americans than in European-Americans. In a sepa-
rate study, carried out in acute coronary syndrome patients, 
carriers of a polymorphism in  kinesin-like protein 6 (KIF-6) 
have been reported to have greater benefi t from pravasta-
tin versus placebo with respect to CVD outcome but not 
with respect to lipid or C-reactive peptide response ( 36 ). 
Additionally, association of the  ABCB1 gene with statin re-
sponse has been reported ( 4, 37 ). Apart from the  APOE 
association, none of these other associations were repli-
cated here. 
 Finally, we note that the effects identifi ed in this study 
are of modest size: the importance of further studying the 
genetics of response to statin therapy may be not in pre-
dicting who will benefi t from statins but in identifying 
other therapeutic targets.  
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